Effect of long-term oral anticoagulant therapy on bone mineral density and bone turnover markers: A prospective 12 month study

Bratislava Medical Journal

Volumn 112, Issue 2, 2011, Pages 71-76

  Stenova, E ^a   Steno, B ^a   Killinger, Z ^a   Baqi, L ^a   Payer, J ^a  

^a Faculty of Natural Sciences   (Slovakia)

Author keywords

Bone mineral density; Bone turnover; Osteoporosis; Vitamin K; Warfarin

Indexed keywords

25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CALCIUM; DRUG DERIVATIVE; VITAMIN D; WARFARIN;

AGED; ARTICLE; BONE DENSITY; BONE REMODELING; DRUG EFFECT; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CALCIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; VITAMIN D; WARFARIN;

EID: 79551675264     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kanis J and the WHO Study Group: Assessment of fracture risk and its applications to screening for postmenopausal osteoporosis of WHO report. Osteoporosis Int 1994; 4: 368-381.
2. Kokavec M, Novorolský K, Pribilincová Z. Possibilities of interdisciplinary intervention of healing of long bone fractures in osteogenesis imperfecta. Acta Chir Orthop Traum Čech 2008; 75: 85-90.
3. Kessler P. Oral anticoagulant therapy. Praha: Orion, 2000.
4. Vermeer C, Hamulyak K. Pathophysiology of vitamin K-deficiency and oral anticoagulants. Thrombosis Haemostasis 1995; 66: 153-159.
5. Hauschka PV, Lian JB, Cole DEC et al. Osteocalcin and matrix Gla protein:vitamin K dependent-proteins in bone. Phys Rev 1989; 69: 990-1047.
6. Plantalech L, Guillaumont M, Leclercq M et al. Impaired carboxylation of serum osteocalcin in elderly women. J Bone Miner Res 1991; 6: 1211-1216.
7. Van Haaerlem LJM, Knapen MHJ, Hamulyák K et al. Circulating osteocalcin during oral anticoagulant therapy. Thrombosis Haemostasis 1988; 60: 79-82.
8. Piro LD, Whyte MP, Murphy WA et al. Normal cortical bone mass in patients after long term coumadin therapy. J Clin Endoc Met 1982; 54 (2): 470-473 .
9. Rosen HN, Maitland LA, Suttie JW et al. Vitamin K and maintenance of skeletal integrity of adults. Am J Med 1993; 94: 62-68.
10. Jamal SA, Browner WS, Bauer DC et al. Warfarin Use and Risk for Osteoporosis in Elderly Women. Ann Int Med 1998; 128: 829-832.
11. Fiore CE, Tamburino C, Foti R et al. Reduced bone mineral content in patients taking an oral anticoagulant. South Med J 1990; 83: 538-542.
12. Monreal M, Olive A, Lafoz E et al. Heparins, coumarin and bone density. Lancet 1991; 338 (8768): 706.
13. Gage BF. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 2006; 23; 166 (2): 241-246.
14. Barnes C. Reduces bone density in children on long-term warfarin. Pediatr Res 2005; 57 (4): 578-581.
15. Wawrzynska L , Tomkowski WZ, Przedlacki J et al. Changes in bone density during long-term administration of LMWH or acenocumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003; 33 (2): 64-67.
16. Iwamoto J, Takeda T, Sato Y. Effects of vitamin K2 on osteoporosis. Curr Pharm Des 2004; 10 (21): 2557-2576.
17. Binkley NC, Krueger DC, Engelke JA et al. Vitamin K supplementation reduces serum concentrations of under-carboxylated osteocalcin in healthy young and elderly adults. Am J Clin Nutr 2000; 72: 1523-1528.
18. Szulc P, Chapuy MC, Meunier PJ et al. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 1996; 18: 487-488.
19. Vergnaud P, Garnero P, Meunier PJ et al. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997; 82: 719-724.
20. Takahashi M, Naitou K, Ohishi T et al. Effect of vitamin K and/or D on undercarboxylated and intact osteocalcin in osteoporotic patients with vertebral or hip fractures. Clin Endocrinol (Oxf) 2001; 54: 219-224.
21. Philip WJ, Martin JC, Richardson JM et al. Decreased axial and peripheral bone density in patients taking long-term warfarin. QJM 1995; 88 (9): 635-640.
22. Sato Y, Honda Y, Kunoh H et al. Long-Term Oral Anticoagulation Reduces Bone Mass in Patients with Previous Hemispheric Infarction and Nonrheumatic Atrial Fibrillation. Stroke 1997; 12: 2390-2394.
23. Sugyiama T. Possible involvements of vitamin K in bone quality. Arch Intern Med 2007; 167 (1): 93-94.
24. Rejnmark L, Vestergaard P, Mosekilde L. Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 2005; 76 (3): 167-175.
25. Rejnmark L, Vestergaard P, Heickendorff L et al. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 2006; 21 (1): 163-170.
26. Iwamoto J, Taked T, Ichimura S. Differential effect of vitamin K and vitamin D supplementation on bone mass in young rats fed normal or low calcium diet. Yonsei Med J 2004; 45 (2): 314-324.
27. Knapen MH, Hamulyák K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med 1989; 15; 111 (12): 1001-1005.
28. Hart JP, Shearer MJ, Klenerman L et al. Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis. J Clin Endocrinol Metab 1985; 60 (6): 1268-1269.
29. Miyake N, Hoshi K, Sano Y et al. 1,25-Dihydroxyvitamin D3 Promotes Vitamin K2 Metabolism in Human Osteoblasts. Ost Int 2001; 12 (8): 680-687.